PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
OBJECTIVES: I. Determine the efficacy of bryostatin 1 administered as a 72-hour continuous
infusion in patients with relapsed multiple myeloma. II. Determine the qualitative and
quantitative toxic effects of bryostatin 1 in these patients. III. Determine the duration of
response and survival following bryostatin 1 in these patients.
OUTLINE: All patients receive bryostatin 1 by 72-hour continuous infusion every 2 weeks
until disease progression or 2 courses beyond complete remission. Response is assessed after
every 4 courses. Patients are followed for survival.
PROJECTED ACCRUAL: A total of 15-25 evaluable patients will be entered into this study over
Primary Purpose: Treatment
Ayad M. Al-Katib, MD, FACP
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
|Barbara Ann Karmanos Cancer Institute
|Detroit, Michigan 48201